Activating Transcription Factor 4 (Atf4) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
title: Activating Transcription Factor 4 (ATF4)
| Activating Transcription Factor 4 (ATF4) |
|---|
| Gene | [ATF4](/genes/atf4) |
| UniProt ID | [Q9Y2K2](https://www.uniprot.org/uniprot/Q9YK2) |
| PDB Structure IDs | 2L7R, 5EOT, 1CI6 |
| Molecular Weight | 38,900 Da (351 amino acids) |
| Subcellular Localization | Nucleus (active transcription factor); cytoplasm (inactive) |
| Protein Family | bZIP transcription factor family (ATF/CREB) |
| Expression | Ubiquitous; high in brain (hippocampus, cortex), pancreas, skeletal muscle |
ATF4 (Activating Transcription Factor 4) is a leucine zipper transcription factor that serves as the master regulator of the integrated stress response (ISR). It controls amino acid metabolism, antioxidant responses, synaptic plasticity, and cellular adaptation to various environmental and metabolic stresses. Dysregulated ATF4 signaling is critically implicated in the pathogenesis of Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), and amyotrophic lateral sclerosis (ALS).
ATF4 is a basic leucine zipper (bZIP) transcription factor belonging to the ATF/CREB family with distinct structural domains:
- N-terminal Regulatory Domain: Contains upstream open reading frames (uORFs) that regulate ATF4 translation in a stress-dependent manner. Under normal conditions, ribosomes translate uORF2 which blocks the main ORF. Under stress, eIF2α phosphorylation shifts translation to the main ORF.
- Basic DNA-binding Region: Recognizes ATF/CRE response elements (TGACGTCA) and related sequences. This domain mediates binding to promoter and enhancer regions of target genes.
- Leucine Zipper Dimerization Domain: Forms homodimers or heterodimers with other bZIP proteins including CHOP (GADD153), C/EBP family members, and Maf proteins. Heterodimer formation expands the regulatory network and determines target gene specificity.
- Transactivation Domain: Rich in acidic residues (glutamine, aspartic acid) in the N-terminus; mediates interaction with transcriptional coactivators (CBP/p300, histone acetyltransferases).
Structural studies reveal that ATF4 adopts a classic bZIP fold with an N-terminal regulatory region that undergoes conformational changes in response to cellular stress signals.
ATF4 is the key transcription factor downstream of the four eIF2α kinases (PERK, GCN2, PKR, HRI) that sense different stress conditions:
- PERK: Activated by endoplasmic reticulum (ER) stress (unfolded protein response)
- GCN2: Activated by amino acid deprivation, ribosome stalling
- PKR: Activated by viral infection (dsRNA)
- HRI: Activated by heme deficiency, oxidative stress
Phosphorylation of eIF2α reduces global translation while selectively promoting ATF4 translation through the uORF mechanism.
ATF4 regulates a wide array of genes involved in:
- Amino Acid Metabolism: Asparagine synthetase (ASNS), phosphoserine aminotransferase (PSAT1), serine hydroxymethyltransferase (SHMT2)
- Antioxidant Response: Cystine/glutamate antiporter (xCT/SLC7A11), heme oxygenase-1 (HO-1)
- Transport: System L amino acid transporter (LAT1/SLC7A5)
- Transcription: CHOP (GADD153), C/EBPβ
- Apoptosis: BIM, PUMA
- Synaptic Plasticity: Repression of synaptic proteins under stress conditions
In the central nervous system, ATF4 plays critical roles in:
- Synaptic Plasticity: Regulates dendritic spine morphology and synaptic transmission. Chronic ATF4 activation can repress synaptic plasticity genes contributing to cognitive deficits.
- Memory Formation: ATF4 is a negative regulator of long-term memory consolidation. Its expression increases in the hippocampus after learning, and ATF4-deficient mice show enhanced memory.
- Neuronal Survival: Context-dependent pro-survival or pro-apoptotic functions depending on stress intensity and duration.
- Astrocyte Function: Regulates astrocyte reactivity and inflammatory responses in the CNS.
ATF4 dysregulation contributes to multiple aspects of AD pathogenesis:
- BACE1 Upregulation: ATF4 directly activates the BACE1 (β-secretase) promoter, increasing amyloid-β production. In AD brain, elevated ATF4 correlates with increased BACE1 expression.
- Tau Pathology: ATF4 regulates tau phosphorylation through effects on GSK-3β and CDK5. Integrated stress signaling exacerbates tau pathology.
- Synaptic Dysfunction: Chronic ATF4 activation represses synaptic plasticity genes including AMPA receptor subunits, NMDA receptor subunits, and PSD-95, contributing to synaptic loss.
- ER Stress: Aβ oligomers trigger PERK-eIF2α-ATF4 signaling, creating a vicious cycle of ER stress and neuronal dysfunction.
- ER Stress Response: ATF4 is activated in response to ER stress from LRRK2 G2019S mutations and α-synuclein aggregation. The ATF4-CHOP pathway contributes to dopaminergic neuron death.
- Mitochondrial Dysfunction: PINK1 and PRKN mutations trigger ATF4-mediated stress responses. ATF4 regulates genes involved in mitochondrial quality control.
- Dopaminergic Vulnerability: Midbrain dopaminergic neurons show heightened sensitivity to ATF4-mediated apoptosis due to their high metabolic demands.
- Transcriptional Dysregulation: Mutant huntingtin (mHTT) directly interacts with ATF4, altering its transcriptional activity. ATF4 target genes are broadly dysregulated in HD models and human brain.
- Energy Metabolism: ATF4 regulates genes controlling mitochondrial function and energy metabolism, which are impaired in HD.
- Aggregation Toxicity: ATF4 may be sequestered into mHTT aggregates, reducing its availability for normal transcriptional regulation.
- ER Stress and CHOP-mediated Apoptosis: In ALS, ATF4-CHOP signaling promotes motor neuron apoptosis. Mutations in SOD1, FUS, and C9orf72 all activate the ISR.
- Protein Homeostasis: ATF4 regulates autophagy genes, and its dysregulation contributes to impaired protein clearance in ALS.
- Excitotoxicity: ATF4 contributes to glutamate excitotoxicity through regulation of excitatory amino acid transporters.
ISRIB is a small molecule that stabilizes eIF2B in its active conformation, bypassing eIF2α phosphorylation and blocking ATF4 translation:
- Mechanism: ISRIB binds eIF2B, preventing the translational block imposed by phospho-eIF2α
- Benefits: Reduces ATF4-mediated pro-apoptotic gene expression while preserving some adaptive responses
- Challenges: ISRIB affects all four stress response branches, requiring careful dosing
- Clinical Status: Preclinical development for neurodegenerative diseases
- Integrated Stress Response Inhibitors: Compounds targeting PERK (e.g., GSK2656157) reduce ATF4 activation but may compromise adaptive ER stress responses.
- GCN2 Inhibitors: Research compounds inhibiting GCN2 are being explored for their neuroprotective effects.
- ATF4 Knockdown: Antisense oligonucleotides (ASOs) targeting ATF4 mRNA are being explored to reduce ATF4 overexpression in disease states.
- Modulating ATF4 Cofactors: Targeting interactions between ATF4 and its cofactors (CBP/p300, CHOP) offers alternative therapeutic approaches.
ATF4 activity can be assessed through:
- Phospho-eIF2α: Downstream marker of ISR activation; elevated in AD, PD, ALS brain and CSF
- ATF4 Target Genes: ASNS, CHOP, xCT (SLC7A11) expression as biomarkers of ATF4 activity
- CHOP (GADD153): Downstream pro-apoptotic target; elevated in neurodegenerative disease
The study of Activating Transcription Factor 4 (Atf4) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.